When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses — in people with relapsed or refractory multiple myeloma, a Phase 1b trial shows. The study’s findings were presented in a poster, titled “Oncolytic virus Pelareorep plus Carfilzomib & Dexamethasone phase I trial in Carfilzomib-refractory patients (NCI 9603): responses with cytokine storm,” at the recent 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Reolysin…
You must be logged in to read/download the full post.
The post Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial appeared first on BioNewsFeeds.